Nokea
Which of the following medications is a potassium-sparing diuretic?
- A. Bumetanide
- B. Hydrochlorothiazide
- C. Spironolactone
- D. Torsemide
Correct Answer: C
Rationale: Spironolactone is a potassium-sparing diuretic, blocking aldosterone, unlike the others which promote potassium loss.
You may also like to solve these questions
Medication agreements or 'Pain Medication Contracts' are recommended to be used:
- A. Universally for all prescribing for chronic pain
- B. For patients who have repeated requests for pain medication
- C. When you suspect a patient is exhibiting drug-seeking behavior
- D. For patients with pain associated with malignancy
Correct Answer: A
Rationale: Pain contracts are recommended universally for chronic pain to set expectations, not just for repeated requests , suspicion , or cancer .
Which of the following drug has the ability to produce hypogliceic effect via closure of ATP-sensitive channels
- A. Glipizide
- B. Metformin
- C. Acarbose
- D. Pramlintide
Correct Answer: A
Rationale: Glipizide, a sulfonylurea, closes ATP-sensitive K+ channels, stimulating insulin release.
While receiving treatment for kidney stones, a man complains of swelling and pain in his big toe and is found to have hyperuricemia
- A. Clomiphene
- B. Hydrochlorothiazide
- C. Furosemide
- D. Mifepristone
Correct Answer: B
Rationale: Thiazides like hydrochlorothiazide reduce uric acid excretion, causing hyperuricemia and gout.
Which medication order requires nursing judgment and means administer if needed?
- A. Morphine 4 mg IV stat
- B. Morphine 4 mg IV prior to procedure
- C. Morphine 4 mg IV four times a day
- D. Morphine 4 mg IV every 4 hours PRN
Correct Answer: D
Rationale: PRN indicates for the nurse to administer morphine every 4 hours if needed and requires nursing judgment. Stat means the dose of morphine would be given immediately, not as needed. The orders for the dose of morphine to be given prior to the patient's scheduled procedure and four times a day, do not indicate to give the dose as needed.
The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
- A. ESAs no longer be prescribed to patients with chronic renal failure
- B. The risk of tumor development be explained to cancer patients on ESA therapy
- C. Patients should no longer receive ESA therapy to prepare for allogenic transfusions
- D. ESAs be prescribed only to patients staying
Correct Answer: B
Rationale: The 2010 FDA warning highlighted tumor progression risks in cancer patients on ESAs; renal use continues with caution.